PAI
ALXN

Palo Alto Investors’s Alexion Pharmaceuticals ALXN Stock Holding History

Palo Alto Investors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-94,850
Closed -$17.4M – 43
2021
Q2 		$17.4M Sell
94,850
-140,426
-60% -$24.1M 0.96% 19
2021
Q1 		$36M Sell
235,276
-268,153
-53% -$41.5M 2.05% 16
2020
Q4 		$78.7M Buy
503,429
+45,900
+10% +$5.9M 4.12% 9
2020
Q3 		$52.4M Buy
457,529
+12,900
+3% +$1.39M 2.87% 11
2020
Q2 		$49.9M Sell
444,629
-197,862
-31% -$21M 3% 12
2020
Q1 		$57.7M Sell
642,491
-235,609
-27% -$23.1M 4.83% 11
2019
Q4 		$95M Sell
878,100
-79,850
-8% -$8.54M 5.23% 9
2019
Q3 		$93.8M Sell
957,950
-65,830
-6% -$7.42M 6.25% 7
2019
Q2 		$134M Sell
1,023,780
-205,250
-17% -$26.5M 6.52% 5
2019
Q1 		$166M Buy
1,229,030
+24,702
+2% +$3.07M 6.93% 5
2018
Q4 		$117M Buy
1,204,328
+4,127
+0.3% +$488K 6.24% 5
2018
Q3 		$167M Buy
1,200,201
+13,774
+1% +$1.73M 6.74% 5
2018
Q2 		$147M Buy
1,186,427
+50,582
+4% +$5.91M 5.89% 6
2018
Q1 		$127M Buy
1,135,845
+18,203
+2% +$2.18M 5.41% 7
2017
Q4 		$134M Buy
1,117,642
+37,300
+3% +$4.54M 5.76% 6
2017
Q3 		$152M Buy
1,080,342
+49,400
+5% +$6.71M 6.38% 6
2017
Q2 		$125M Buy
1,030,942
+3,882
+0.4% +$452K 5.86% 5
2017
Q1 		$125M Buy
1,027,060
+313,318
+44% +$40.4M 5.89% 5
2016
Q4 		$87.3M Buy
713,742
+152,042
+27% +$18.6M 4.98% 6
2016
Q3 		$68.8M Buy
561,700
+222,300
+65% +$28.6M 4% 8
2016
Q2 		$39.6M Buy
+339,400
New +$48.2M 2.99% 11

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Palo Alto Investors's ALXN Position: Q3 2021 in Review

Palo Alto Investors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 94,850 shares — an estimated $17.4M sold.

Palo Alto Investors first reported a position in ALXN in Q2 2016 and held it in 21 quarters. The position peaked at $167M in Q3 2018. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Palo Alto Investors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Palo Alto Investors sold 94,850 Alexion Pharmaceuticals shares in Q3 2021, an estimated $17.4M.
  • Palo Alto Investors first reported a position in Alexion Pharmaceuticals in Q2 2016 and held it in 21 quarters.
  • Palo Alto Investors's Alexion Pharmaceuticals position peaked at $167M in Q3 2018.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Palo Alto Investors's 13F filing for Q3 2021, filed 15 Nov 2021.